Mrs. Alderman oversees a team of researchers involved in clinical trials under the direction of principal investigator Lin Sikich, MD at the Duke Center for Autism and Brain Development. She received a bachelor’s degree in science (biology and psychology) from the University of North Carolina at Chapel Hill and subsequently obtained her CCRP (Certified Clinical Research Professional) certificate from the Society of Clinical Research Associates in 2012. The focus of her work is on industry funded and investigator initiated (federally funded) research to find better treatments for children, adolescents and adults with an autism spectrum disorder.
In her role at Duke, Mrs. Alderman manages various aspects of clinical trials from budget development/grant submissions to study implementation which includes regulatory compliance and protocol adherence. Mrs. Alderman supervises study coordinators, research assistants and recruitment coordinators in order to ensure that they conduct the highest quality research in accordance with ethical standards while still providing compassionate care for our study participants.
Mrs. Alderman also conducts a variety of assessments and is research reliable on both the Autism Diagnostic Observation Scale (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R). Over her career, she has experience administering multiple neurocognitive assessments on individuals with a myriad of disorders including autism spectrum, Fragile X, bipolar disorder and psychotic disorders such as schizophrenia. Additionally, she serves as one of the center’s phlebotomists.
Mrs. Alderman has been working with individuals with autism since 2005. She has worked both in a group for children and adolescents and a day program for adults with an autism spectrum disorder.
1. Reeves GM, Keeton C, Correll CU, Johnson JL, Hamer RM, Sikich L, Hazzard L, Alderman C, Scheer A, Mabe M, Kapoor S, Sheridan E, Borner I, Bussell K, Pirmohamed S, Bethea TC, Chekuri R, Gottfried R, Reinblatt SP, Santana E, Riddle MA. Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolescent Psychiatry Mental Health. 2013 Aug 15;7 (1):31.